NASDAQ:ABEO Abeona Therapeutics Q3 2025 Earnings Report $5.38 -0.09 (-1.65%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$5.48 +0.09 (+1.77%) As of 10/17/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Abeona Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.27Beat/MissN/AOne Year Ago EPSN/AAbeona Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$5.53 millionBeat/MissN/AYoY Revenue GrowthN/AAbeona Therapeutics Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time7:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Abeona Therapeutics Earnings HeadlinesHC Wainwright & Co. Reiterates Abeona Therapeutics (ABEO) Buy RecommendationOctober 13, 2025 | msn.comAbeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot ProgramOctober 13, 2025 | globenewswire.comNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.October 18 at 2:00 AM | Brownstone Research (Ad)3 Top Growth Stocks Insiders Are Eager To HoldOctober 10, 2025 | finance.yahoo.comAbeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene TherapyOctober 8, 2025 | globenewswire.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2025 | globenewswire.comSee More Abeona Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abeona Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abeona Therapeutics and other key companies, straight to your email. Email Address About Abeona TherapeuticsAbeona Therapeutics (NASDAQ:ABEO) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need. The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa. These candidates have advanced through early‐stage trials, offering initial proof of concept in delivering corrective genetic material to affected tissues. Abeona is also exploring innovative oncology cell therapy approaches that apply its gene delivery expertise to tumor targeting. Abeona supports its pipeline with cGMP manufacturing facilities in Cleveland and Cambridge, complemented by a research presence in the Texas Medical Center to scale vector production and process development. The company has forged strategic collaborations to streamline clinical supply and broaden patient access, reflecting its commitment to advancing transformative medicines globally. Under the guidance of its executive leadership, Abeona continues to engage with regulatory authorities and expand clinical trial initiatives across North America and Europe.View Abeona Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Nasdaq (10/21/2025)Texas Instruments (10/21/2025)Intuitive Surgical (10/21/2025)Netflix (10/21/2025)Verizon Communications (10/21/2025)General Motors (10/21/2025)CocaCola (10/21/2025)Citigroup (10/21/2025)3M (10/21/2025)RTX (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
